Dianthus Therapeutics Stock Performance
| DNTH Stock | 53.59 0.20 0.37% |
On a scale of 0 to 100, Dianthus Therapeutics holds a performance score of 16. The firm shows a Beta (market volatility) of -0.59, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Dianthus Therapeutics are expected to decrease at a much lower rate. During the bear market, Dianthus Therapeutics is likely to outperform the market. Please check Dianthus Therapeutics' coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Dianthus Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dianthus Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite fairly conflicting basic indicators, Dianthus Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.0562 | Five Day Return 3.27 | Year To Date Return 34.55 | Ten Year Return (77.02) | All Time Return (77.02) |
Last Split Factor 1:16 | Last Split Date 2023-09-12 |
1 | Analysts Set Dianthus Therapeutics, Inc. Price Target at 63.43 | 11/24/2025 |
2 | Is Dianthus Therapeutics Inc. stock overvalued by current metrics - CPI Data AI Enhanced Trading Signals - | 12/19/2025 |
3 | Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 In Healthy Volunteers and Patients With Systemic Lupus Erythematosus | 12/23/2025 |
4 | Dianthus Therapeutics, Inc. DNTH Stake Lessened by Moody Aldrich Partners LLC - MarketBeat | 01/02/2026 |
5 | Dianthus CFO Sells 20,000 Shares for 903,600 After Massive Year-End Run | 01/07/2026 |
6 | Is Dianthus Therapeutics Inc. currently under institutional pressure - July 2025 Setups Growth Oriented Trading Recommendations - bollywoodhelpline.com | 01/14/2026 |
7 | Dianthus Therapeutics Trading Up 10.3 percent Time to Buy | 01/22/2026 |
8 | Dianthus Therapeutics may issue up to 600 million in securities - marketscreener.com | 01/28/2026 |
| Begin Period Cash Flow | 132.4 M | |
| Total Cashflows From Investing Activities | -286.8 M | |
| Free Cash Flow | -78.3 M |
Dianthus Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,320 in Dianthus Therapeutics on November 4, 2025 and sell it today you would earn a total of 2,019 from holding Dianthus Therapeutics or generate 60.81% return on investment over 90 days. Dianthus Therapeutics is currently generating 0.8631% in daily expected returns and assumes 4.1438% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Dianthus, and 83% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dianthus Therapeutics Target Price Odds to finish over Current Price
The tendency of Dianthus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 53.59 | 90 days | 53.59 | near 1 |
Based on a normal probability distribution, the odds of Dianthus Therapeutics to move above the current price in 90 days from now is near 1 (This Dianthus Therapeutics probability density function shows the probability of Dianthus Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Dianthus Therapeutics has a beta of -0.59 suggesting as returns on the benchmark increase, returns on holding Dianthus Therapeutics are expected to decrease at a much lower rate. During a bear market, however, Dianthus Therapeutics is likely to outperform the market. Additionally Dianthus Therapeutics has an alpha of 0.7959, implying that it can generate a 0.8 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Dianthus Therapeutics Price Density |
| Price |
Predictive Modules for Dianthus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dianthus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dianthus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Dianthus Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dianthus Therapeutics is not an exception. The market had few large corrections towards the Dianthus Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dianthus Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dianthus Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.80 | |
β | Beta against Dow Jones | -0.59 | |
σ | Overall volatility | 5.09 | |
Ir | Information ratio | 0.18 |
Dianthus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dianthus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dianthus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dianthus Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 3.08 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Dianthus Therapeutics may issue up to 600 million in securities - marketscreener.com |
Dianthus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dianthus Stock often depends not only on the future outlook of the current and potential Dianthus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dianthus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 33.3 M | |
| Cash And Short Term Investments | 275.2 M |
Dianthus Therapeutics Fundamentals Growth
Dianthus Stock prices reflect investors' perceptions of the future prospects and financial health of Dianthus Therapeutics, and Dianthus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dianthus Stock performance.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (101.74) % | ||||
| Current Valuation | 1.91 B | ||||
| Shares Outstanding | 43.22 M | ||||
| Price To Book | 4.22 X | ||||
| Price To Sales | 749.73 X | ||||
| Revenue | 6.24 M | ||||
| Gross Profit | 3.08 M | ||||
| EBITDA | (101.45 M) | ||||
| Net Income | (84.97 M) | ||||
| Total Debt | 1.49 M | ||||
| Book Value Per Share | 12.75 X | ||||
| Cash Flow From Operations | (78.18 M) | ||||
| Earnings Per Share | (3.50) X | ||||
| Market Capitalization | 2.31 B | ||||
| Total Asset | 374.01 M | ||||
| Retained Earnings | (174.39 M) | ||||
| Working Capital | 262.45 M | ||||
About Dianthus Therapeutics Performance
By evaluating Dianthus Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Dianthus Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dianthus Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dianthus Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.22) | (0.23) |
Things to note about Dianthus Therapeutics performance evaluation
Checking the ongoing alerts about Dianthus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dianthus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dianthus Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 6.24 M. Net Loss for the year was (84.97 M) with profit before overhead, payroll, taxes, and interest of 3.08 M. | |
| Dianthus Therapeutics generates negative cash flow from operations | |
| Dianthus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Dianthus Therapeutics may issue up to 600 million in securities - marketscreener.com |
- Analyzing Dianthus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dianthus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dianthus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dianthus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dianthus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dianthus Therapeutics' stock. These opinions can provide insight into Dianthus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |